Business Context and Reporting Period
Company: CareDx, Inc.
Filing Type: Form 8-K (Current Report)
Date of Report: September 11, 2014
Event: Entry into a Material Definitive Agreement (Settlement and Mutual Release) with Roche Molecular Systems, Inc.
Key Financial Metrics and Settlement Terms
The filing details a settlement regarding a long-standing dispute over royalty payments for the AlloMap service under a 2004 license agreement.
- Settlement Payment (Past Due): $2,827,220 agreed to be paid for the period July 1, 2011, through June 30, 2014.
- Accrued Liability (as of June 30, 2014): $3,525,534 (included royalty liability and related interest).
- Future Royalty Terms:
- July 1, 2014 – Sept 30, 2014: Royalties based on the disputed combination services percentage.
- Oct 1, 2014 – Sept 30, 2017: Downward adjustment to the combination services percentage.
- After Sept 30, 2017: No further royalties payable, subject to timely payments.
- Payment Schedule: Quarterly royalties due within 45 days of the end of each calendar quarter.
Material Changes and Historical Context
Dispute Resolution: CareDx had withheld royalty payments from July 2011 through September 2014 due to a disagreement over the "combination services percentage" multiplier. Roche filed for arbitration on February 11, 2014. This settlement resolves the arbitration and the underlying dispute.
Accounting Impact: The company had fully accrued the unpaid royalties and interest claimed by Roche since July 1, 2011. The settlement amount of $2,827,220 is less than the accrued liability of $3,525,534 recorded as of June 30, 2014, indicating a reduction in the previously recognized liability.
Breakdown of Settlement Payment:
- Six months ended Dec 31, 2011: $399,633
- Year ended Dec 31, 2012: $887,837
- Year ended Dec 31, 2013: $975,257
- Six months ended June 30, 2014: $564,493
Outlook, Risks, and Management Commentary
Future Obligations: The agreement caps royalty obligations for the AlloMap service through September 30, 2017, after which no further royalties are payable under this agreement, provided all payments are made on time.
Risk Mitigation: The mutual release eliminates all claims under the license agreement through the settlement date and dismisses the pending arbitration claims, removing a significant legal contingency.
Operational Impact: The downward adjustment to the combination services percentage for the period starting October 1, 2014, is expected to reduce future royalty expenses compared to the disputed rate.
Investor Verification Checklist
- Verify the cash outflow impact of the $2,827,220 settlement payment on the company's liquidity in the quarter of payment.
- Confirm the accounting treatment of the difference between the accrued liability ($3,525,534) and the settlement amount ($2,827,220) in the income statement.
- Monitor future quarterly filings to ensure the new, downward-adjusted royalty rate is applied correctly starting October 1, 2014.
- Review the company's cash flow projections to ensure they can meet the new quarterly payment schedule within 45 days of quarter-end.